The first half of the year shows stability in the sales results of JSC Olainfarm
In the first six months of 2020 Olainfarm Group successfully continued its operations in the core markets and ensured growth of medicines supplied within its primary therapeutic areas, which allowed the Group to reach EUR 66 million sales, a similar amount of sales compared to the same time period last year.
The Group's main market in the first half of 2020 was Russia, representing 30% of total sales, while the products for the health of the nervous system reached 53% of medical product sales, the growth was mainly led by increased sales of Adaptol.
“I look back at the first six months of this year and rate it as a dynamic time full of learning. Our main focus was to provide uninterrupted accessibility of our products to the patients we serve in our core markets, in a backdrop of Covid-19 related challenges. Also, it is important to highlight that we have finished work with the company's 5 year strategy transforming to sustainable year-over-year double digit growth in our core segments of prescription products, OTC products and our APIs. In the first half of this year, our focus was on securing our existing business and business in the long-term. A critical strategic lever is to optimize our R&D activities fueling the portfolio with new products. Now we are ready to bring it to the next level by accelerating growth, leading to a significant increase of the company's value. I am pleased to report that our work so far is reflected in the financial results of the first half of the year,” said Jeroen Weites, Chairperson of the Management Board of JSC Olainfarm.
Groups reported EBITDA for the first six months of 2020 is EUR 17.9 million, which is a 19% increase compared to the same time period last year, while the net profit is EUR 10 million, which is a 18% decline due to the currency exchange losses resulting from the Ruble exchange rate fluctuations in the reporting period.
Although the Group has implemented comprehensive security measures and was able to continuously supply products due to its vertically integrated manufacturing structure, some markets experienced a decline in demand due to changes in purchasing power and limitations to acquire medical products. Due to the changes in demand, the Group has decreased the sales forecast for 2020 to EUR 126 million, which is a 7% decline to the previously reported. The forecasted net profit for the Group in 2020 is EUR 11.2 million, which is a EUR 3 million decline compared to the prior forecast due to negative exchange rate fluctuations.
JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in the production of medicines and chemical pharmaceutical products. The basic principle of the company's activity is to produce reliable and efficient products of the highest quality for Latvia and the whole world. Currently, the products of JSC Olainfarm are exported to more than 50 countries and territories of the world, including the Baltic States, Russia, other CIS countries, Europe, North America, Asian countries and Australia.
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cavotec e-truck charging wins major award23.9.2020 08:00:00 CEST | Press release
An innovative high-power e-truck charging solution, developed by Cavotec in partnership with the Port of Long Beach (POLB) and International Transportation Service (ITS), has won the American Association of Port Authorities (AAPA) 2020 Facilities Engineering Award. The POLB Smart e-Truck Charging pilot project enables the rapid and efficient high-power charging of battery powered heavy-duty terminal tractors thereby offering substantial operational, safety, and environmental benefits. The system includes a fixed 150 kW charging unit located in the container yard which extends and connects to a receptacle retrofitted on each e-truck ensuring safe, hands-free operation, easy connection and maintenance, and rapid charging. The project, in its pilot phase, involves retrofitting one out of a total of 650 conventionally powered terminal tractors that are currently in use at POLB, so the potential for improvements in operational efficiency and environmental impact are considerable. “The techn
Maha Energy AB (publ) – Announces an operational update23.9.2020 07:51:42 CEST | Press release
Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press Release Stockholm September 23, 2020 Maha Energy AB (publ) – Announces an operational update Maha’s 2 x 1,380 HP compression project at Tie has been successfully commissionedDrilling rig is now onsite at the “Tie 2” location in Brazil and has commenced drilling Maha Energy AB ("Maha" or the "Company") today announce an operational update for its activities in Brazil and the United States. Jonas Lindvall, President and Chief Executive Officer of Maha, comments: "Notwithstanding Covid-19 continuing to challenge some of our operations we have achieved two important milestones at the Tie Field. We are very happy to announce commencement of our gas compression and injection project and the spud of the next production well at the Tie field.” Operational update Tie Field Compression Project During the month of August, a dedicated commissioning team has been onsite to commission the two 1,380 HP compression units
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program23.9.2020 07:15:00 CEST | Press release
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September23, 2020– Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study to supplement the existing STRONG data and further support the regulatory submission for AVXS-101 IT. This guidance provides clarity on the path to registration for AVXS-101 IT. Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This reques
AND (Ticker: AND.AS) intends to rebrand the company22.9.2020 18:05:00 CEST | Press release
Supporting the turnaround and the new strategic direction of the company Capelle aan den IJssel, the Netherlands, 22 September 2020 - AND is happy to announce that it intends to change the company name and refresh its branding in Q4 2020. This change is designed to highlight the company’s new strategic direction as well as support and strengthen the transformation into a subscription based provider of premium location aware content and services. As announced on August 12th, the turnaround strategy has already delivered 22% revenue growth in the first half of 2020. AND believes the new company name and branding will help to drive continued revenue growth and put location-intelligence squarely at the center of the company’s profile. Further announcements will follow in Q4 2020. Ends About AND AND is an innovative location-aware content and service provider. Our focus is to create and deliver market leading, relevant, innovative and tailored content which fosters a safer and more sustaina
Wolters Kluwer Completes Divestment of ComplyTrack22.9.2020 17:30:00 CEST | Press release
Wolters Kluwer Completes Divestment of ComplyTrack September 22, 2020 - Wolters Kluwer announces today that it has completed the divestment of ComplyTrack to symplr, as originally announced on September 8, 2020. About Wolters Kluwer Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services. Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolt
Joint Stock Company “Olainfarm” Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 has not been held due to lack of quorum22.9.2020 14:20:00 CEST | Press release
Joint Stock Company “Olainfarm” Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 has not been held due to lack of quorum Joint Stock Company “Olainfarm” Management Board informs that for the Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 pm shareholders who in total represented 3 877 425 voting shares or 27.53% of voting capital were registered, therefore shareholders' meeting did not take place due to lack of quorum. Olaine, September 22, 2020 Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Ph.: +371 29178878 email@example.com